GANAB and cancer: Section 2 discusses the enzyme’s molecular architecture and catalytic mechanism. Section 3 explores different classes of GluII inhibitors, including natural and synthetic compounds, and their structure–activity relationships. Section 4 examines the biological and clinical implications of GluII inhibition, focusing on cancer and viral infections, while Section 5 highlights challenges, knowledge gaps, and perspectives for future drug development.